Creyon Bio is a pioneering brand that is revolutionizing drug development and enabling on-demand oligonucleotide therapeutics. They are driven by a mission to reimagine the drug development process, from discovery to engineering. With their powerful and purpose-built data sets, Creyon Bio engineers oligonucleotide-based medicines (OBMs), providing safe and precise gene-centric therapies with unmatched speed and predictable efficacy and safety.

Their groundbreaking modular approach significantly reduces costs for developing new medicines, whether for individual patients or large populations. Creyon Bio collaborates with various stakeholders, including industry partners, patient advocates, and policymakers, to deliver gene-centric medicines quickly and effectively to those who need them the most. Creyon Bio's multidisciplinary team of chemists, biologists, and computational scientists dares to color outside the lines, tackling the drug development challenge from all angles.

If you're ready to build a better world of drug development, join them as a Creyoneer and help create a faster, more streamlined, and more equitable process for developing new medicines. Stay updated with the latest news from Creyon Bio, as they continue to make waves in the industry. Their work has been featured in various publications, including the Decoding Bio Snapshot and the Deep Tech Opportunities Report by DCVC